Blog
RSS FeedPosted by Michael Wonder on 19 Nov 2020
Trifarotene in moderate acne: no study data for the assessment of the added benefit
16 November 2020 - Only studies with placebo comparisons despite many affected people and existing treatment alternatives. ...
Posted by Michael Wonder on 05 Nov 2020
IQWiG publishes a new version of its general methods
5 November 2020 - New features include the investigation of volume-outcome relationships and different mean observation times in clinical studies. ...
Posted by Michael Wonder on 01 Oct 2020
Fostamatinib in chronic immune thrombocytopenia: added benefit not proven due to lack of comparison
1 October 2020 - Only placebo controlled studies in the dossier. ...
Posted by Michael Wonder on 29 Sep 2020
Germany has not fully realised its biosimilar potential
29 September 2020 - Investigators have concluded that fully realizing the cost-saving potential of biosimilars could “release enormous resources” for ...
Posted by Michael Wonder on 21 Sep 2020
Second joint meeting on ‘Innovations in Healthcare’
18 September 2020 - How can methodological and scientific advice to manufacturers of medicinal products be further optimised at European level ...
Posted by Michael Wonder on 17 Sep 2020
The best possible security of supply for cancer therapy with CAR-T cells
17 September 2020 - Medical facilities that treat patients with novel cell therapies (CAR-T cells) must meet newly defined quality requirements. ...
Posted by Michael Wonder on 02 Sep 2020
Talazoparib in breast cancer: hint of considerable added benefit
1 September 2020 - Advantages in health related quality of life, symptoms and side effects outweigh disadvantages. ...
Posted by Michael Wonder on 27 Aug 2020
Mylan, Lupin launch etanercept biosimilar in Germany
26 August 2020 - The launch marks the first European market entry for Nepexto. ...
Posted by Michael Wonder on 17 Aug 2020
Castration-resistant prostate cancer with a high risk of metastasis: enzalutamide has an additional benefit
17 August 2020 - New data from the PROSPER study shows benefit in overall survival. ...
Posted by Michael Wonder on 13 Aug 2020
Predictors of negotiated prices for new drugs in Germany
13 August 2020 - In Germany, all new, innovative medicines are subject to an early benefit assessment by the German Federal ...
Posted by Michael Wonder on 06 Aug 2020
Darolutamide in prostate cancer: indication of considerable added benefit
3 August 2020 - Advantages in overall survival, symptoms and health-related quality of life. ...
Posted by Michael Wonder on 17 Jul 2020
Determination of the target population in early benefit assessments in Germany: challenges for non-small-cell lung cancer
17 July 2020 - Dossiers submitted for early benefit assessments in Germany also provide information on the precise determination of the ...
Posted by Michael Wonder on 11 Jul 2020
How can cancer drug prices better match their benefits? Germany offers a cost-saving model
10 July 2020 - After Germany revamped its approach to purchasing medicines a decade ago, the prices negotiated by the ...
Posted by Michael Wonder on 07 Jul 2020
Lessons from the impact of price regulation on the pricing of anti-cancer drugs in Germany
7 July 2020 - Worldwide spending on prescription drugs has increased dramatically in recent years. Although this increase has been particularly ...
Posted by Michael Wonder on 07 Jul 2020
Network meta-analyses: no compensation for weak evidence
7 July 2020 - BMJ publication headed by IQWiG: relevant controlled studies and individual patient data are necessary for informative ...